Confluence Wealth Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Confluence Wealth Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$816K	Buy	1,642 +1,095	+200%	+$485K	0.02%	262
2026 Q1	$244K	Buy	547 +2	+0.4%	+$933	0.01%	339
2025 Q4	$247K	Buy	545 +21	+4%	+$9.05K	0.01%	341
2025 Q3	$205K	Buy	+524	New	+$219K	0.01%	361
2024 Q3	–	Sell	-762	Closed	-$357K	–	373
2024 Q2	$357K	Buy	+762	New	+$331K	0.03%	271
2022 Q1	–	Sell	-363	Closed	-$79K	–	1147
2021 Q4	$79K	Buy	+363	New	+$70.6K	0.03%	371

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Confluence Wealth Services's VRTX Position: Q2 2026 in Review

Confluence Wealth Services increased its Vertex Pharmaceuticals (VRTX) stake by 200% in Q2 2026, buying an estimated $485K and bringing the position to 1,642 shares worth $816K. The position accounts for 0.02% of the portfolio, ranked #262.

Confluence Wealth Services first reported a position in VRTX in Q4 2021 and has held it in 6 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Confluence Wealth Services held 1,642 shares of Vertex Pharmaceuticals worth $816K as of Q2 2026.
Confluence Wealth Services bought 1,095 Vertex Pharmaceuticals shares in Q2 2026, an estimated $485K.
Vertex Pharmaceuticals made up 0.02% of Confluence Wealth Services's portfolio in Q2 2026, its #262 holding.
Confluence Wealth Services first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Confluence Wealth Services's 13F filing for Q2 2026, filed 22 Jul 2026.